AmpliPhi Biosciences (NYSEAMERICAN:APHB) was the target of a large decline in short interest in the month of March. As of March 29th, there was short interest totalling 1,103,899 shares, a decline of 9.5% from the March 15th total of 1,219,178 shares. Currently, 7.1% of the company’s shares are short sold. Based on an average trading volume of 535,566 shares, the short-interest ratio is currently 2.1 days.
In other AmpliPhi Biosciences news, Director Jeremy Curnock Cook acquired 46,666 shares of the company’s stock in a transaction that occurred on Thursday, November 22nd. The stock was purchased at an average price of $7.40 per share, for a total transaction of $345,328.40. Following the completion of the acquisition, the director now owns 330 shares of the company’s stock, valued at approximately $2,442. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of NYSEAMERICAN:APHB opened at $1.19 on Wednesday. AmpliPhi Biosciences has a twelve month low of $0.67 and a twelve month high of $5.00.
AmpliPhi Biosciences (NYSEAMERICAN:APHB) last issued its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.11. AmpliPhi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million.
Separately, HC Wainwright set a $6.00 price target on shares of AmpliPhi Biosciences and gave the stock a “buy” rating in a report on Thursday, March 15th.
AmpliPhi Biosciences Company Profile
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
Receive News & Ratings for AmpliPhi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmpliPhi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.